+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Narcolepsy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830086
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 81 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Axsome Therapeutics Inc
  • Bioprojet SCR
  • F. Hoffmann-La Roche Ltd
  • Jazz Pharmaceuticals Plc
  • Ono Pharmaceutical Co Ltd
  • Seelos Therapeutics Inc
  • MORE
High levels of pipeline activity are being observed in Narcolepsy treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc, Balance Therapeutics Inc, Bioprojet SCR, Evotec AG and others.

A Significant contribution to the Narcolepsy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Narcolepsy pipeline included 20 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Narcolepsy condition and increased access to investments is encouraging growth of Narcolepsy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Narcolepsy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Narcolepsy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Narcolepsy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Narcolepsy. Further, orphan drug status, fast track designation, grants awarded and other special status for Narcolepsy pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Narcolepsy pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Narcolepsy Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Narcolepsy drugs
  • Late phase: Phase 3 and in-approval Narcolepsy drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Narcolepsy therapeutic treatment activities
Details for each Narcolepsy drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Narcolepsy therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Axsome Therapeutics Inc
  • Bioprojet SCR
  • F. Hoffmann-La Roche Ltd
  • Jazz Pharmaceuticals Plc
  • Ono Pharmaceutical Co Ltd
  • Seelos Therapeutics Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Narcolepsy- Disease Overview
2.2 Narcolepsy- Pipeline Snapshot
2.3 Narcolepsy- Pipeline Drugs by Phase
2.4 Narcolepsy- Pipeline Drugs by Company
2.5 Narcolepsy- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Avadel Pharmaceuticals Plc Narcolepsy Drug Pipeline, H2- 2019
3.2 Axsome Therapeutics Inc Narcolepsy Drug Pipeline, H2- 2019
3.3 Balance Therapeutics Inc Narcolepsy Drug Pipeline, H2- 2019
3.4 Bioprojet SCR Narcolepsy Drug Pipeline, H2- 2019
3.5 Evotec AG Narcolepsy Drug Pipeline, H2- 2019
3.6 F. Hoffmann-La Roche Ltd Narcolepsy Drug Pipeline, H2- 2019
3.7 H.A.C. Pharma Narcolepsy Drug Pipeline, H2- 2019
3.8 Jazz Pharmaceuticals Plc Narcolepsy Drug Pipeline, H2- 2019
3.9 NLS Pharmaceutics Ltd Narcolepsy Drug Pipeline, H2- 2019
3.10 Ono Pharmaceutical Co Ltd Narcolepsy Drug Pipeline, H2- 2019
3.11 OptiNose US Inc Narcolepsy Drug Pipeline, H2- 2019
3.12 Seelos Therapeutics Inc Narcolepsy Drug Pipeline, H2- 2019
3.13 SK Biopharmaceuticals Co Ltd Narcolepsy Drug Pipeline, H2- 2019
3.14 Sosei Heptares Narcolepsy Drug Pipeline, H2- 2019
3.15 SRI International Narcolepsy Drug Pipeline, H2- 2019
3.16 Suven Neurosciences Inc Narcolepsy Drug Pipeline, H2- 2019
3.17 Taisho Pharmaceutical Holdings Co Ltd Narcolepsy Drug Pipeline, H2- 2019
3.18 Takeda Pharmaceutical Co Ltd Narcolepsy Drug Pipeline, H2- 2019
3.19 Theranexus SAS Narcolepsy Drug Pipeline, H2- 2019
3.20 XW Laboratories Inc Narcolepsy Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Narcolepsy- Phase 1 Drug Details
4.2 Narcolepsy- Phase 1 Drug Overview
4.3 Narcolepsy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Narcolepsy- Phase 2 Drug Details
5.2 Narcolepsy- Phase 2 Drug Overview
5.3 Narcolepsy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Narcolepsy- Phase 3 Drug Details
6.2 Narcolepsy- Phase 3 Drug Overview
6.3 Narcolepsy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Narcolepsy- Pre-clinical Phase Drug Details
7.2 Narcolepsy- Pre-clinical Phase Drug Overview
7.3 Narcolepsy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Avadel Pharmaceuticals Plc
  • Axsome Therapeutics Inc
  • Balance Therapeutics Inc
  • Bioprojet SCR
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • H.A.C. Pharma
  • Jazz Pharmaceuticals Plc
  • NLS Pharmaceutics Ltd
  • Ono Pharmaceutical Co Ltd
  • OptiNose US Inc
  • Seelos Therapeutics Inc
  • SK Biopharmaceuticals Co Ltd
  • Sosei Heptares
  • SRI International
  • Suven Neurosciences Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Theranexus SAS
  • XW Laboratories Inc
Note: Product cover images may vary from those shown
Adroll
adroll